Marianne Jansson
Titel
doc, fo.ass
Organisation
046-173271
Marianne [dot] Jansson [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2013
- 2012
- Dual R3R5 tropism characterizes cerebrospinal fluid (CSF) HIV-1 isolates from individuals with high CSF viral load.
- Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load
- Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.
- Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection
- Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1
- R5 HIV-1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children.
- Tuberculosis and HIV Co-Infection
- 2011
- 2010
- Increased sensitivity to neutralizing antibodies of end-stage disease R5 HIV-1 is concomitant with reduced gp120 glycosylation and increased plus charge
- Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.
- Microbial Translocation Correlates with the Severity of Both HIV-1 and HIV-2 Infections
- 2009
- Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
- Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
- Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid Isolates.
- Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections
- 2008
- Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-I variants emerging during AIDS progression
- Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
- Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin
- 2005
- Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets
- Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation
- Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
- 2004
